Stockreport

Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting [Yahoo! F...

Nuvalent, Inc. - Class A  (NUVL) 
NASDAQ:AMEX Investor Relations: nuvelinc.com/company/investor_relations.html
PDF CAMBRIDGE, Mass. April 21, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapi [Read more]